Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  02/19/2010
 
Trade Name:  MENVEO
 
Generic or Proper Name (*):  Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine*
 
Indications Studied:  Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
 
Therapeutic Category:  Preventive Vaccine
 
Ages Studied:  11  18 years
 
Study #:  2
 
Study Type:  Safety/Immunogenicity
 
Study Design:  Open Label/Controlled
 
No Patients:  1620
 
No Centers:  1
 
No Countries:  1
 
BPCA(B), PREA(P):  P
 
-
-